CARsgen Completed $60 Million Pre-C Financing Framework Agreements

SHANGHAI, March 2, 2018 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a leading immune-oncology company focusing on the development of CAR-T therapies, today announces it has entered into a Pre-C financing framework agreement with rec... Biopharmaceuticals, Oncology, Venture Capital CARsgen Therapeutics, CAR-T therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news